Lille, France, October 23, 2025 – LATTICE MEDICAL, a French Medtech company specializing in tissue engineering, announces a Series B fundraising round of €43 million, one of the largest of the year in the French Medtech sector. This major milestone will enable the company to accelerate the clinical development of its MATTISSE medical device, a […]
BRISBANE, Australia, Aug. 25, 2025 (GLOBE NEWSWIRE) — Vaxxas Pty Ltd, the biotechnology company pioneering the high-density microarray patch (HD-MAP) for needle-free vaccine delivery, today announced that it has secured ~$90 million in its latest financing round. The financing is one of the largest financings for a private biotech company in Australia this year and […]
GHENT, Belgium–(BUSINESS WIRE)–Azalea (A-zuh-lay-ah) Vision, a HealthTech company engineering the future of sight, today announced the first closing of its €15 million Series A funding round, raising €9 million along with the appointment of Robert J. Dempsey as Chairman of the Board to guide strategic growth in the European and U.S. markets. I believe a […]
Company focused on editing the human leukocyte antigen (HLA) to transform autoimmunity Lead program, RG0401, in development for treatment-resistant or refractory rheumatoid arthritis (RA), as a one-time, curative treatment AURORA, CO, January 9, 2025 – RheumaGen, Inc., a cell and gene therapy company engineering a new class of therapeutics for major autoimmune diseases, announced today […]
The funds will support two Phase 2a clinical trials for the drug candidate CIL001, targeting cochlear synaptopathy (a leading cause of difficulty understanding speech in noise, tinnitus, and hyperacusis), as well as the advancement of preclinical development for the candidate CIL003. The company will enhance its R&D platform capabilities and establish new strategic partnerships to […]
July 25, 2024 – (PRNewswire) – ObvioHealth, a global digital clinical trials company, announces a new strategic investment by Guardant Health, Inc., a leading precision oncology company offering liquid and tissue biopsy tests across the cancer research and care continuum. The alliance strengthens ObvioHealth’s domain expertise in oncology and enables streamlined deployment of oncology clinical […]
June 18, 2024 – (Forbes Australia) – Founder and CEO Mimi Tang has spent almost three decades working in allergy immunology. For much of that time, she was unsatisfied with the common approach – avoid the allergen and turn to the EpiPen in an emergency. But, after an initial trial in 2015 showed hope for […]
Financing advances development of Prota’s peanut allergy remission therapy in preparation for a Phase 3 clinical trial MELBOURNE, Jan 16, 2024 – (ACN Newswire) – Prota Therapeutics Pty Ltd (Prota), an Australian biotechnology company focused on the development of novel oral immunotherapy treatments that induce remission of allergy, today announced financing of US$21 million in […]
SINGAPORE, May 26, 2023 – SPRIM Global Investments (SPRIM), a leading health sciences investment firm, completed an equity investment in VCTC Limited, a UK-based specialist clinical trial site. SPRIM funding will enable VCTC to expedite growth through expansion of services and access to wider cross-portfolio opportunities. This investment is part of SPRIM’s strategy to build […]
Ad hoc announcement pursuant to Art. 53 LR SGI debt facility to provide Spexis up to half of the projected ColiFin® Phase 3 development costs, including those involving both COPILOT and COPA SGI has invested in Spexis as part of the ColiFin® P3 clinical trial partnership financing; additional investments from other investors expected in the […]
- 1
- 2